帕妥珠单抗靶向治疗对人表皮生长因子受体2阳性晚期乳腺癌患者生活质量及预后的影响

Effect of Pertuzumab Targeted Therapy on the Quality of Life and Prognosis of Patients with Human Epidermal Growth Factor Receptor 2 Positive Advanced Breast Cancer

目的:探讨帕妥珠单抗靶向治疗对人表皮生长因子受体2(HER-2)阳性晚期乳腺癌患者生活质量及预后的影响。方法:选择2016年1月-2017年12月期间河南省省立医院收治的HER-2阳性晚期乳腺癌患者84例,采用随机数字表法分为两组,各42例。对照组行常规治疗,观察组加用帕妥珠单抗治疗。比较两组生活质量、预后及毒副反应。结果:两组治疗后生活质量评分均升高,且观察组高于对照组,观察组总生存期(23.76±1.41)个月、肿瘤无进展生存期(16.45±1.26)个月,长于对照组(20.39±1.38)个月、(12.63±1.17)个月,观察组毒副反应发生率(4.76%)低于对照组(21.43%),差异有统计学意义(P<0.05)。结论:HER-2阳性晚期乳腺癌患者采用帕妥珠单抗靶向治疗效果较好,利于延长患者生存时间,减少治疗过程中的毒副反应,从而提高生活质量,改善预后。

Objective: To explore the effect of Pertuzumab targeted therapy on the quality of life and prognosis of patients with human epidermal growth factor receptor 2(HER-2) positive advanced breast cancer. Methods: From January 2016 to December2017, 84 patients with HER-2 positive advanced breast cancer admitted to the hospital were divided into two groups by random number table method, each group with 42 cases. The control group received conventional treatment, and the observation group was treated with Pertuzumab. The quality of life, prognosis and toxicity of the two groups were compared. Results: The quality of life scores of the two groups increased after treatment, and the observation group was higher than the control group. The overall survival period of the observation group was(23.76±1.41) months, and the tumor progression-free survival period was(16.45±1.26)months, which were longer than(20.39±1.38) months and(12.63±1.17) months in the control group. The reaction rate(4.76%) was lower than that of the control group(21.43%), and the difference was statistically significant(P<0.05). Conclusion: Pertuzumab targeted therapy for patients with HER-2 positive advanced breast cancer has a better effect, which is beneficial to prolong the survival time of patients, reduce toxic and side effects during the treatment process, thereby improving the quality of life and improving the prognosis.